Synergic Induction of Autophagic Cell Death in Anaplastic Thyroid Carcinoma

References

• Ragazzi M, Ciarrocchi A, Sancisi V, Gandolfi G, Bisagni A, Piana S. Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol. 2014;2014:790834. doi:10.1155/2014/790834.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16(1):17–44. doi:10.1677/ERC-08-0154.
   PubMed Web of Science ®Google Scholar
• Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997;79(3):564–573. doi:10.1002/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0.
   PubMed Web of Science ®Google Scholar
• Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330–1335. doi:10.1002/cncr.20936.
   PubMed Web of Science ®Google Scholar
• Lin B, Ma H, Ma M, Zhang Z, Sun Z, Hsieh IY, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res. 2019;11(9):5888–5896.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104–1139.
   PubMed Web of Science ®Google Scholar
• McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery. 2001;130(6):1028–1034. doi:10.1067/msy.2001.118266.
   PubMed Web of Science ®Google Scholar
• Broecker-Preuss M, Müller S, Britten M, Worm K, Schmid KW, Mann K, Fuhrer D. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer. 2015;15(1):184. doi:10.1186/s12885-015-1186-0.
   PubMedGoogle Scholar
• Cantara S, Bertelli E, Occhini R, Regoli M, Brilli L, Pacini F, et al. Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine. 2019;64(1):122–129. doi:10.1007/s12020-019-01865-5.
   PubMed Web of Science ®Google Scholar
• Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24–33. doi:10.1016/j.molmed.2014.10.009.
   PubMed Web of Science ®Google Scholar
• Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76(23):6964–6974.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen W, Xu ZP, Gu W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2019;10:2022.
   PubMed Web of Science ®Google Scholar
• Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget. 2016;7(13):17194–17211. doi:10.18632/oncotarget.7839.
   PubMedGoogle Scholar
• Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021;31(7):1076–1085. doi:10.1089/thy.2020.0322.
   PubMed Web of Science ®Google Scholar
• Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018;6(1):68.
   PubMedGoogle Scholar
• Denton D, Xu T, Kumar S. Autophagy as a pro-death pathway. Immunol Cell Biol. 2015;93(1):35–42. doi:10.1038/icb.2014.85.
   PubMed Web of Science ®Google Scholar
• Di Fazio P, Waldegger P, Jabari S, Lingelbach S, Montalbano R, Ocker M, et al. Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer. Oncotarget. 2016;7(20):28998–29010.
   PubMedGoogle Scholar
• Robainas M, Otano R, Bueno S, Ait-Oudhia S. Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy. Onco Targets Ther. 2017;10:1803–1807. doi:10.2147/OTT.S132508.
   PubMed Web of Science ®Google Scholar
• Yu HI, Shen HC, Chen SH, Lim YP, Chuang HH, Tai TS, et al. Autophagy modulation in human thyroid cancer cells following aloperine treatment. Int J Mol Sci. 2019;20(21):5315.
   Google Scholar
• Di Fazio P, Schneider-Stock R, Neureiter D, Okamoto K, Wissniowski T, Gahr S, et al. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol. 2010;32(4):285–300.
   PubMedGoogle Scholar
• Matrood S, de Prisco N, Wissniowski T, Wiese D, Jabari S, Griesmann H, et al. Modulation of pancreatic neuroendocrine neoplastic cell fate by autophagy mediated death. Neuroendocrinology. 2021;111(10):965–985.
   PubMedGoogle Scholar
• Wirries A, Jabari S, Jansen EP, Roth S, Figueroa-Juárez E, Wissniowski TT, et al. Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma. Oncotarget. 2018;9(68):32997–33010.
   PubMedGoogle Scholar
• Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27–42. doi:10.1016/j.cell.2007.12.018.
   PubMed Web of Science ®Google Scholar
• Wei W, Rosenkrans ZT, Luo QY, Lan X, Cai W. Exploiting nanomaterial-mediated autophagy for cancer therapy. Small Methods. 2019;3(2):1800365. doi:10.1002/smtd.201800365.
   PubMed Web of Science ®Google Scholar
• Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet. 2015;24(8):2318–2329.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Aurora-Garg D, Albright A, Xu L, Liu XQ, Loboda A, et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer. 2022;10(1):e003091. doi:10.1136/jitc-2021-003091.
   PubMedGoogle Scholar
• Eckhardt S, Hoffmann S, Damanakis AI, Di Fazio P, Pfestroff A, Luster M, et al. Individualized multimodal treatment strategy for anaplastic thyroid carcinoma-case report of long-term remission and review of literature. Int J Surg Case Rep. 2016;25:174–178. doi:10.1016/j.ijscr.2016.06.013.
   PubMedGoogle Scholar
• Wächter S, Damanakis AI, Elxnat M, Roth S, Wunderlich A, Verburg FA, et al. Epigenetic modifications in thyroid cancer cells restore NIS and radio-iodine uptake and promote cell death. J Clin Med. 2018;7(4):61.
   Web of Science ®Google Scholar
• Wächter S, Wunderlich A, Roth S, Mintziras I, Maurer E, Hoffmann S, et al. Individualised multimodal treatment strategies for anaplastic and poorly differentiated thyroid cancer. J Clin Med. 2018;7(5):115.
   Google Scholar
• Schildhaus HU. [Predictive value of PD-L1 diagnostics]. Pathologe. 2018;39(6):498–519. doi:10.1007/s00292-018-0507-x.
   PubMed Web of Science ®Google Scholar
• Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007;3(5):452–460. doi:10.4161/auto.4451.
   PubMed Web of Science ®Google Scholar
• Plantinga TS, van de Vosse E, Huijbers A, Netea MG, Joosten LA, Smit JW, Netea-Maier RT. Role of genetic variants of autophagy genes in susceptibility for non-medullary thyroid cancer and patients outcome. PLoS One. 2014;9(4):e94086. doi:10.1371/journal.pone.0094086.
   PubMedGoogle Scholar
• Plantinga TS, Tesselaar MH, Morreau H, Corssmit EP, Willemsen BK, Kusters B, et al. Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer. Autophagy. 2016;12(7):1195–1205. doi:10.1080/15548627.2016.1174802.
   PubMed Web of Science ®Google Scholar
• Di Fazio P, Matrood S. Targeting autophagy in liver cancer. Transl Gastroenterol Hepatol. 2018;3:39. doi:10.21037/tgh.2018.06.09.
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 2021;17(1):1–382. doi:10.1080/15548627.2020.1797280.
   PubMed Web of Science ®Google Scholar
• Matrood S, de Prisco N, Wissniowski TT, Wiese D, Jabari S, Griesmann H, et al. Modulation of pancreatic neuroendocrine neoplastic cell fate by autophagy-mediated death. Neuroendocrinology. 2021;111(10):965–985.
   PubMed Web of Science ®Google Scholar
• De Leo S, Trevisan M, Fugazzola L. Recent advances in the management of anaplastic thyroid cancer. Thyroid Res. 2020;13(1):17. doi:10.1186/s13044-020-00091-w.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, et al. Novel treatments for anaplastic thyroid carcinoma. Gland Surg. 2020;9(S1):S28–S42. doi:10.21037/gs.2019.10.18.
   PubMedGoogle Scholar
• Spartalis E, Athanasiadis DI, Chrysikos D, Spartalis M, Boutzios G, Schizas D, et al. Histone deacetylase inhibitors and anaplastic thyroid carcinoma. Anticancer Res. 2019;39(3):1119–1127.
   PubMed Web of Science ®Google Scholar
• Wächter S, Wunderlich A, Greene BH, Roth S, Elxnat M, Fellinger SA, et al. Selumetinib activity in thyroid cancer cells: modulation of sodium iodide symporter and associated miRNAs. Int J Mol Sci. 2018;19(7):2077.
   PubMedGoogle Scholar
• Gandesiri M, Chakilam S, Ivanovska J, Benderska N, Ocker M, Di Fazio P, et al. DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions. Apoptosis. 2012;17(12):1300–1315.
   PubMed Web of Science ®Google Scholar
• Tsapras P, Nezis IP. Caspase involvement in autophagy. Cell Death Differ. 2017;24(8):1369–1379. doi:10.1038/cdd.2017.43.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang H, Hu C, Wu C, Wang J, Hu F, et al. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma. Cell Death Dis. 2021;12(2):164.
   PubMedGoogle Scholar
• Ahn S, Kim TH, Kim SW, Ki CS, Jang HW, Kim JS, et al. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer. 2017;24(2):97–106.
   PubMed Web of Science ®Google Scholar
• Hegedűs L, Rittler D, Garay T, Stockhammer P, Kovács I, Döme B, et al. HDAC inhibition induces PD-L1 expression in a novel anaplastic thyroid cancer cell line. Pathol Oncol Res. 2020;26(4):2523–2535. doi:10.1007/s12253-020-00834-y.
   PubMed Web of Science ®Google Scholar
• Zwaenepoel K, Jacobs J, De Meulenaere A, Silence K, Smits E, Siozopoulou V, et al. CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy. Histopathology. 2017;71(3):357–365. doi:10.1111/his.13230.
   PubMedGoogle Scholar
• Li Y, Fei Y, Liu L, Song Z, Meng X, Qiu L, et al. Programmed cell death protein 1/programmed cell death ligand-1 axis activates intracellular ERK signaling in tumor cells to mediate poor prognosis in T-cell lymphoma. J Cancer. 2021;12(20):6126–6134.
   PubMedGoogle Scholar
• Moore A, Bar Y, Maurice-Dror C, Finkel I, Goldvaser H, Dudnik E, et al. Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: a multicenter experience. Medicine. 2021;100(25):e26388. doi:10.1097/MD.0000000000026388.
   PubMed Web of Science ®Google Scholar
• Scheffel RS, Dora JM, Maia AL. BRAF mutations in thyroid cancer. Curr Opin Oncol. 2021;34(1):9–18.
   PubMedGoogle Scholar
• Stenman A, Yang M, Paulsson JO, Zedenius J, Paulsson K, Juhlin CC. Pan-genomic sequencing reveals actionable. Cancers. 2021;13(24):6340.
   Google Scholar
• Hescheler DA, Hartmann MJM, Riemann B, Michel M, Bruns CJ, Alakus H, Chiapponi C. Anaplastic thyroid cancer: genome-based search for new targeted therapy options. Endocr Connect. 2022;11(4):e210624.
   PubMedGoogle Scholar
• Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13. doi:10.1200/JCO.2017.73.6785.
   PubMed Web of Science ®Google Scholar